Related by context. Frequent words. (Click for all words.) 63 active comparator 63 dose cohorts 61 Phase IIa trial 60 multicenter randomized double 60 Phase Ib 60 PROMACTA 60 LIALDA 60 muraglitazar 60 phase IIb 60 Jevtana 59 mixed dyslipidemia 59 Iluvien 59 dose escalation trial 59 Phase 1b trial 59 Phase 1b 59 Phase 2b trial 59 ONGLYZA 59 hepatitis C HCV 59 dacarbazine 58 Phase 2b study 58 TORISEL 58 blind randomized placebo 58 Phase 2a trial 58 randomized Phase III 58 diabetic neuropathic pain 58 COPAXONE ® 58 BAY #-# 58 placebo controlled 58 Cladribine Tablets 58 Bronchitol 58 Taxotere ® 58 phase IIa 58 COPAXONE R 58 PROPEL trial 58 PEG INTRON 58 blinded placebo controlled 57 plus methotrexate 57 JANUVIA 57 Complete Response 57 vicriviroc 57 peginterferon alfa 2a 57 dose escalation study 57 dose escalation 57 rotigotine 57 peg IFN 57 relapsed multiple myeloma 57 tgAAC# 57 Marketing Authorization Application 57 chronic HCV infection 57 mg BID 57 multicenter clinical 57 Phase 2a 57 refractory multiple myeloma 57 REVLIMID R 57 DSMB 57 Phase III randomized 57 composite endpoint 57 Investigational Device Exemption IDE 57 multicentre 57 methylnaltrexone 57 Phase III pivotal 57 FOLFIRI 57 Torisel 57 sitagliptin 56 tesmilifene 56 blind randomized 56 label dose escalation 56 Phase IIb trial 56 Phase 2b 56 axitinib 56 Phase 1b clinical 56 SUTENT 56 randomized Phase 56 STELARA 56 RG# [001] 56 TELCYTA 56 Phase III clinical 56 Nimotuzumab 56 tocilizumab 56 ACTEMRA 56 BYDUREON 56 placebo controlled trials 56 double blind placebo 56 NUVIGIL 56 Phase IIb 56 valopicitabine 55 ISENTRESS 55 CoFactor 55 Phase Ia 55 mcg kg 55 Phase III clinical trials 55 mg doses 55 Phenoptin 55 pivotal Phase III 55 dabigatran etexilate 55 randomized placebo controlled 55 dose regimens 55 Phase 2b clinical 55 confirmatory Phase 3 55 INCB# [002] 55 sustained virologic response